TuHURA Biosciences, Inc.
corporate_fare Company Profile
TuHURA Biosciences, Inc. (NASDAQ:HURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for HURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for HURA spans 10-Q, DEF 14A, 8-K, PRE 14A.
Recent high-impact activity:
- TuHURA 10-Q: $1.9M Cash, $18.1M Nine-Month Burn, 49.2M Dilutive Shares Outstanding
- TuHURA Secures U.S. Patent for DOR ADC Platform, Bolstering Pipeline
- FDA Clears TuHURA's TBS-2025 VISTA Antibody for Phase 1b AML Trial
- TuHURA Q2 2026: $1.0M Cash, $50M Credit Facility Draws, CEO 10b5-1 Plan
- TuHURA Reports Q2 Cash of $1.0M, Files IND for AML Drug, Maps 2H Milestones
Financial Snapshot
Short Interest & Short Volume
12.63 days to coverFINRA reported short interest of 6,203,722 shares in HURA as of the October 30, 2026 settlement, a 4.5% increase from the prior period — about 12.6 days to cover at its recent average daily volume. On November 20, 2026, 56.6% of HURA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for HURA, detected from its recent SEC filings · based on capital-structure filings through 2026-06-26.
Shareholder Vote on Equity Issuance · Critical Funding Secured
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →